GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

The National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending GSK’s Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for ...

NHS England has confirmed that it will be the first health system worldwide to roll out the treatment. The drug will be ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...

A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

England becomes the first country to offer the world’s pioneering 'Trojan horse' blood cancer drug, through NHS, promising ...

New therapy nearly triples disease-free survival time for some patients with bone marrow cancer in world-first recommendation ...